AccuShares(R) Investment Management, LLC ("AccuShares")

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AccuShares(R) Investment Management, LLC ("AccuShares") Announces an Estimated Regular and Net Income (if Applicable) Distributions for Both AccuShares S&P GSCI Crude Oil Excess Return Up Shares and Down Shares

STAMFORD, CT --(Marketwired - July 08, 2016) - AccuShares, as sponsor of the AccuShares Trust I (formerly known as the AccuShares Commodity Trust I) (the "Trust"), today announces an estimated Regular Distribution and, if applicable, an estimated Net Income Distribution for AccuShares S&P GSCI Crude Oil Excess Return Up Shares ( NASDAQ : OILU ) (the "Up Shares") and S&P GSCI Crude Oil Excess Return Down Shares ( NASDAQ : OILD ) (the "Down Shares"). The terms Regular Distribution and Net Income Distribution are defined and described in the current prospectus of the AccuShares S&P GSCI Crude Oil Excess Return Fund (the "Fund").

The Estimated Distribution amounts below are calculated as of July 8, 2016 and therefore such information is only an estimate, is subject to change and may be significantly different from the actual distribution amounts to be declared, which will be published on the date of declaration. The Estimated Distribution information below has been determined as if the closing value of the S&P GSCI Crude Oil Excess Return Index (the "Underlying Index") for July 8, 2016 were the closing value of the Underlying Index at the end of the current Regular Distribution measurement period.

The relevant estimated distribution information is provided in the tables below:

Distribution Dates :

                 
NASDAQ Ticker   Name   Ex-Date   Record Date   Distribution Payment Date
OILU   AccuShares S&P GSCI Crude Oil Excess Return Up Shares   July 18, 2016   July 20, 2016   July 22, 2016
OILD   AccuShares S&P GSCI Crude Oil Excess Return Down Shares   July 18, 2016   July 20, 2016   July 22, 2016
                 

Estimated Distribution Amount Information :

                       
NASDAQ  Ticker Name   Closing Index Value as of July 08, 2016   Post-Distribution Share Index Factor*   Post-Distribution Class Value per Share*   Net Income Distribution Amount per share   Regular Distribution Amount per share
OILU AccuShares S&P GSCI Crude Oil Excess Return Up Shares   159.51   0.15359539   $24.50   $0.000000   $0.000000
OILD AccuShares S&P GSCI Crude Oil Excess Return Down Shares   159.51   -0.15359539   $24.50   $0.000000   $0.992496
                       

* As defined in the Fund's prospectus.

Investor Reassessment:

Investors wishing to maximize exposure to the index tracked by the Fund, the S&P GSCI Crude Oil Excess Return Index, in either direction or investors wishing to compound gains over one or more distribution dates must invest any cash distributed, and sell any shares distributed and invest the sale proceeds thereof, in the class of shares aligned with their investment objectives.

The Fund has been designed to be utilized by investors who are prepared to reassess their holding of the Fund's shares at least as frequently as each distribution date. Investors in the Fund who wish to maintain a maximum exposure, a targeted absolute exposure, or a targeted relative exposure to the Underlying Index over multiple distribution dates should reassess their positions following all cash and share distributions, and all Fund resets relating to the Share Index Factors. The Fund will not compound investor gains or otherwise rebalance investor positions to maximize investor exposure. The Fund is designed to make Regular Distributions of cash and in some cases shares to facilitate regular distribution of investor gains and to promote a deliberate and regular reassessment by investors of their investment in the Fund.

Investors who hold shares over one or more consecutive distribution dates without reassessment of their Fund share portfolio may experience decreased exposure to the Underlying Index as well as a reduced opportunity for gain and loss.

About AccuShares:

Founded in 2011, AccuShares Investment Management, LLC, ( www.accushares.com ) develops and sponsors innovative exchange traded funds (ETFs) in key alternative asset classes, including oil and volatility. The company holds a series of technology patents that provide the basis for a more institutional approach to constructing index-based products, enhancing tracking accuracy and transparency while reducing fund costs.

Disclosures:

Neither the Trust nor the Fund is an investment company within the meaning of the Investment Company Act of 1940 and neither is subject to regulation thereunder. Although AccuShares is registered as a commodity pool operator with the Commodity Futures Trading Commission ("CFTC"), the Trust and the Fund are not subject to regulation under the Commodities Exchange Act or by the CFTC. Consequently Fund shareholders are not afforded the regulatory protections provided to investors in registered investment companies or commodity pools.

Investing in the Funds involves substantial risk and high volatility, including possible loss of principal. Shares of the Fund are intended for sophisticated, professional and institutional investors. The Fund is not intended to be used as a long-term passive investment vehicle and should be used by investors who understand the risks of the volatility market. Investors expecting the Underlying Index to decline should purchase the Fund's Down Shares, and investors expecting the Underlying Index to increase should purchase the Fund's Up Shares, to align their respective Fund investments with their respective expectations. Please read the Fund's prospectus carefully before investing. The Fund's prospectus can be obtained by clicking the link below.

http://www.accushares.com/resources/vix-fund-prospectus

The Trust is a Delaware statutory trust organized by AccuShares into separate fund series. The Fund's shares represent fractional undivided interests in and ownership of the Fund only and not any other series of the Trust or the Trust as a whole. The Fund offers its shares on a continuous basis and is listed on the NASDAQ.

Disclaimers:

The "The S&P GSCI® Crude Oil" is a product of S&P Dow Jones Indices LLC or its affiliates ("SPDJI") and, and has been licensed for use by AccuShares Management LLC. Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by AccuShares Management LLC. AccuShares Crude Oil Fund is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P GSCI Crude Oil.

Foreside Fund Services, LLC Marketing Agent

AccuShares Investor Service Center 1-855-286-7866 info@accushares.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 39

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 116

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 139

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 385

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

IONQ Achieves Record Stock Levels Amid Strong Growth Indicators

Updated Category News Views 243

IONQ Stock Reaches New Heights Recently, IONQ has made headlines as its stock skyrocketed to an unprecedented level of $47.41, marking a significant achievement for the company. With a robust market capitalization of $10.2 billion, this remarkable performance is a testament to the company's impressive growth trajectory and the strong belief investors hold in its future....

Continue Reading
Model 1 Commercial Vehicles Expands Leadership Team for Growth

Updated Category News Views 285

Model 1 Commercial Vehicles Announces Leadership Changes Model 1 Commercial Vehicles is thrilled to unveil a set of key leadership appointments aimed at enhancing its strategic direction and ensuring the company's ongoing success. These changes reflect the impressive growth trajectory the company has experienced over the past few years. Tony Matijevich Takes the Helm as...

Continue Reading
Texas Instruments: Unusual Options Trends Uncovered

Updated Category News Views 195

Texas Instruments Options Insights Financial powerhouses have made a notable bullish move on Texas Instruments. Our analysis reveals intriguing trends within the options market for Texas Instruments (NASDAQ: TXN), showcasing an unusual number of trades that pinpoint shifting market sentiments. Trading Sentiment Overview Diving deeper into the data, it appears that 58% of...

Continue Reading
SMCP Unveils Latest Interim Financial Report for 2025

Updated Category News Views 177

SMCP Announces Availability of Its Interim Financial Report SMCP is excited to share that its interim financial report for the six-month period ending June 30, 2025, is now available for public access. This report has been officially filed with the relevant regulatory authorities. Details on the Financial Report This financial report outlines the company's performance...

Continue Reading
Kevin O'Leary Discusses Business Leaders' Support for Trump

Updated Category News Views 159

Understanding O'Leary's Perspective on Business Leadership Kevin O’Leary, a prominent entrepreneur and investor from Shark Tank, has provided insight into the evolving relationship between business leaders and President Trump. In recent discussions, O’Leary emphasized that the admiration many tech CEOs and corporate leaders have for Trump is not solely about his tax...

Continue Reading